Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Kanda Biotechnology Co. Ltd. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This suggests a focused prosecution strategy, likely revolving around a single biotechnology innovation or a specific pharmaceutical application that the company is currently seeking to protect.
The prosecution is handled by 1 distinct examiner and is located within 1 distinct art unit. This concentration indicates that the company's current patenting efforts are being reviewed by a single individual within a single administrative group. Such a centralized process can be beneficial for maintaining a consistent prosecution narrative, as there are no competing viewpoints from other examiners or art units to consider during the review of the 1 pending office action.
AEDER, SEAN E is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Because this examiner is responsible for the only pending action, their specific review will determine the immediate success of the company's intellectual property strategy. Practitioners should analyze the examination history of this examiner to better anticipate their concerns and effectively resolve the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036156 | ANTI-HER-2 ANTIBODY-CHEMOKINE FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036156 | ANTI-HER-2 ANTIBODY-CHEMOKINE FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036156 | ANTI-HER-2 ANTIBODY-CHEMOKINE FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | AEDER, SEAN E | 1642 | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial